Advanced Oncotherapy plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that on Monday 8th and Tuesday 9th May 2017, Professor Chris Nutting, Non-Executive Director of the Company, purchased a total of 202,500 ordinary shares of 25 pence in the Company (“Ordinary Shares”) at an average price of 24.67 pence per Ordinary Share.
Following these transactions, Professor Nutting holds 217,316 Ordinary Shares, representing 0.29% of the Company’s share capital as enlarged by the issue of new Ordinary Shares notified on 8th May 2017.
Advanced Oncotherapy plc is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy’s team “ADAM”, based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.